{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:29:16Z","timestamp":1788820156112,"version":"build-2803163510"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>T-cell engagers (TCEs) are a diverse class of bispecific and multispecific molecules that co-bind CD3 on T cells and tumor-associated antigens to form an immune synapse and induce targeted T-cell\u2013mediated cytotoxicity. While TCEs have demonstrated remarkable efficacy in hematologic malignancies, translation into solid tumors has been more challenging. Recent advances seen with tebentafusp in metastatic uveal melanoma and tarlatamab in small-cell lung cancer have validated the approach and driven a rapidly expanding pipeline targeting other tumor associated antigens such as STEAP1, MUC16, and PRAME among others. Unique challenges in solid tumors include antigen heterogeneity and density thresholds, on-target\/off-tumor toxicities, and physical and immunologic barriers within the tumor microenvironment. To address these, next-generation engineering strategies, such as half-life extension, protease- or context-dependent masking, multispecificity, and \u201carmed\u201d constructs incorporating cytokine or co-stimulatory payloads, are being developed to enhance intratumoral activity while limiting systemic toxicities. Combination regimens with checkpoint blockade, chemotherapy, targeted therapies, and oncolytic platforms are also being actively investigated to overcome immune resistance and improve durability of response. Collectively, next-generation TCEs guided by rational target selection, context-dependent activation, and biomarker-driven patient stratification, are poised to broaden the reach of immunotherapy in solid tumors. In this review, we synthesize the recent advances that aim to expand the therapeutic window of TCEs for the treatment of solid tumors.<\/jats:p>","DOI":"10.1093\/oncolo\/oyag129","type":"journal-article","created":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T11:34:33Z","timestamp":1775561673000},"source":"Crossref","is-referenced-by-count":5,"title":["Landscape of T-cell engagers in solid tumors"],"prefix":"10.1093","volume":"31","author":[{"given":"Esther","family":"Garcia-Lorenzo","sequence":"first","affiliation":[{"name":"START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid,","place":["Spain"]},{"name":"Instituto Investigaci\u00f3n Sanitaria Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Dorta","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid,","place":["Spain"]},{"name":"Instituto Investigaci\u00f3n Sanitaria Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Doger","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid,","place":["Spain"]},{"name":"Instituto Investigaci\u00f3n Sanitaria Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Pedregal","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid,","place":["Spain"]},{"name":"Instituto Investigaci\u00f3n Sanitaria Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6099-4236","authenticated-orcid":false,"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[{"name":"START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundaci\u00f3n Jim\u00e9nez D\u00edaz , Madrid,","place":["Spain"]},{"name":"Instituto Investigaci\u00f3n Sanitaria Hospital Fundaci\u00f3n Jim\u00e9nez D\u00edaz (IIS-FJD) , Madrid,","place":["Spain"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"2026042618470701900_oyag129-B1","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B2","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti\u2013PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B3","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"2026042618470701900_oyag129-B5","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"2026042618470701900_oyag129-B6","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"2026042618470701900_oyag129-B8","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"2026042618470701900_oyag129-B9","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-019-0028-1","article-title":"Bispecific antibodies: a mechanistic review of the pipeline","volume":"18","author":"Labrijn","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"2026042618470701900_oyag129-B10","doi-asserted-by":"crossref","first-page":"4941","DOI":"10.1158\/0008-5472.CAN-09-0547","article-title":"Bispecific T-cell engaging antibodies for cancer therapy","volume":"69","author":"Baeuerle","year":"2009","journal-title":"Cancer Res"},{"key":"2026042618470701900_oyag129-B11","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tibtech.2004.03.006","article-title":"A revival of bispecific antibodies","volume":"22","author":"Kufer","year":"2004","journal-title":"Trends Biotechnol"},{"key":"2026042618470701900_oyag129-B12","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B13","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B14","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"2026042618470701900_oyag129-B15","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for relapsed or refractory diffuse large B-cell lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B16","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"2026042618470701900_oyag129-B17","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B18","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"2026042618470701900_oyag129-B19","doi-asserted-by":"crossref","first-page":"7021","DOI":"10.1073\/pnas.92.15.7021","article-title":"A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity","volume":"92","author":"Mack","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"2026042618470701900_oyag129-B20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nm.2764","article-title":"Monoclonal TCR-redirected tumor cell killing","volume":"18","author":"Liddy","year":"2012","journal-title":"Nat Med"},{"key":"2026042618470701900_oyag129-B21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00262-014-1525-z","article-title":"ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells","volume":"63","author":"Bossi","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"2026042618470701900_oyag129-B22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.coi.2015.12.007","article-title":"The urgent need to recover MHC class I in cancers for effective immunotherapy","volume":"39","author":"Garrido","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"2026042618470701900_oyag129-B23","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.it.2015.02.008","article-title":"Overcoming T cell exhaustion in infection and cancer","volume":"36","author":"Pauken","year":"2015","journal-title":"Trends Immunol"},{"key":"2026042618470701900_oyag129-B24","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a TCR\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B25","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1182\/blood-2010-09-306449","article-title":"Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma","volume":"117","author":"Moore","year":"2011","journal-title":"Blood"},{"key":"2026042618470701900_oyag129-B26","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","article-title":"IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function","volume":"22","author":"Vallera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B27","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"32","author":"Correnti","year":"2018","journal-title":"Leukemia"},{"key":"2026042618470701900_oyag129-B28","doi-asserted-by":"crossref","first-page":"3286","DOI":"10.1158\/1078-0432.CCR-15-1696","article-title":"A novel carcinoembryonic antigen T-cell bispecific antibody (CEA TCB) for the treatment of solid tumors","volume":"22","author":"Bacac","year":"2016","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/nature22395","article-title":"Therapeutic T cell engineering","volume":"545","author":"Sadelain","year":"2017","journal-title":"Nature"},{"key":"2026042618470701900_oyag129-B30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"key":"2026042618470701900_oyag129-B31","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"2026042618470701900_oyag129-B32","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"2026042618470701900_oyag129-B33","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"2026042618470701900_oyag129-B34","doi-asserted-by":"crossref","first-page":"8015","DOI":"10.1200\/JCO.2024.42.16_suppl.8015","article-title":"DeLLphi-301: tarlatamab phase 2 trial in small cell lung cancer (SCLC)\u2014efficacy and safety analyzed by presence of brain metastasis","volume":"42","author":"Dingemans","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B35","doi-asserted-by":"publisher","first-page":"3004","DOI":"10.1200\/JCO.2025.43.16_suppl.3004","article-title":"Efficacy and safety of the DLL3\/CD3 T-cell engager obrixtamig in patients with extrapulmonary neuroendocrine carcinomas with high or low DLL3 expression: Results from an ongoing phase I trial","volume":"43","author":"Capdevila","year":"2025","journal-title":"JCO"},{"key":"2026042618470701900_oyag129-B36","doi-asserted-by":"crossref","first-page":"S1367","DOI":"10.1016\/j.annonc.2025.08.3369","article-title":"2758MO updated results from a phase I\/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers","volume":"36","author":"Beltran","year":"2025","journal-title":"Ann Oncol"},{"key":"2026042618470701900_oyag129-B37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1158\/2159-8290.CD-23-0964","article-title":"Xaluritamig, a STEAP1 \u00d7 CD3 XmAb 2\u2009+\u20091 immune therapy for metastatic castration-resistant prostate cancer: results from dose exploration in a first-in-human study","volume":"14","author":"Kelly","year":"2024","journal-title":"Cancer Discov"},{"key":"2026042618470701900_oyag129-B38","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1200\/JCO-25-00678","article-title":"Pasritamig, a first-in-class, bispecific T-cell engager targeting human kallikrein 2, in metastatic castration-resistant prostate cancer: a phase I study","volume":"43","author":"Stein","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B39","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1158\/1078-0432.CCR-23-2978","article-title":"A phase I study of acapatamab, a half-life extended, PSMA-targeting bispecific T-cell engager for metastatic castration-resistant prostate cancer","volume":"30","author":"Dorff","year":"2024","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B40","doi-asserted-by":"crossref","first-page":"TPS5632","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS5632","article-title":"A phase 1\/2 study of ubamatamab (REGN4018), a MUC16\u00d7CD3 bispecific antibody, administered alone or in combination with cemiplimab (anti\u2013PD-1) in patients with recurrent ovarian cancer or MUC16+ endometrial cancer","volume":"42","author":"Van Nieuwenhuysen","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B41","doi-asserted-by":"crossref","first-page":"9507","DOI":"10.1200\/JCO.2024.42.16_suppl.9507","article-title":"Phase 1 safety and efficacy of IMC-F106C, a PRAME \u00d7 CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM)","volume":"42","author":"Hamid","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B42","first-page":"S834","article-title":"Safety and preliminary efficacy of IBI389, a CLDN18.2\u00d7CD3 bispecific antibody, in patients with advanced solid tumors","volume":"34","author":"Zhang","year":"2023","journal-title":"Ann Oncol"},{"key":"2026042618470701900_oyag129-B43","doi-asserted-by":"crossref","first-page":"S1121","DOI":"10.1016\/j.annonc.2025.08.2756","article-title":"2137P ASP2138 monotherapy in patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, advanced solid tumors: phase I\/Ib trial","volume":"36","author":"Shitara","year":"2025","journal-title":"Ann Oncol"},{"key":"2026042618470701900_oyag129-B44","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1038\/s41467-024-48479-8","article-title":"CEA-CD3 bispecific antibody cibisatamab with or without atezolizumab in patients with CEA-positive solid tumours: results of two multi-institutional phase 1 trials","volume":"15","author":"Segal","year":"2024","journal-title":"Nat Commun"},{"key":"2026042618470701900_oyag129-B45","article-title":"Emerging treatments in HER2-positive advanced breast cancer: Keep raising the bar","volume":"5","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026042618470701900_oyag129-B46","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/s13046-019-1354-1","article-title":"A novel asymmetrical anti-HER2\/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells","volume":"38","author":"Yu","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B47","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1158\/1078-0432.CCR-20-3392","article-title":"Preclinical characterization of HPN536, a trispecific, T-cell-activating protein construct for the treatment of mesothelin-expressing solid tumors","volume":"27","author":"Molloy","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B48","doi-asserted-by":"crossref","first-page":"5013","DOI":"10.1200\/JCO.2021.39.15_suppl.5013","article-title":"Results of an ongoing phase 1\/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mcrpc)","volume":"39","author":"De Bono","year":"2021","journal-title":"JCO"},{"key":"2026042618470701900_oyag129-B49","article-title":"A phase 1, first-in-human study of CTIM-76, a claudin-6 (CLDN6)-directed bispecific antibody, in patients with recurrent ovarian cancer and other advanced solid tumors","volume":"43","author":"O\u2019Cearbhaill","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B50","doi-asserted-by":"crossref","first-page":"3028","DOI":"10.1038\/s41591-025-03783-8","article-title":"CLDN18.2\u2013targeting antibody\u2013drug conjugate IBI343 in advanced gastric or gastroesophageal junction adenocarcinoma: a phase 1 trial","volume":"31","author":"Liu","year":"2025","journal-title":"Nat Med"},{"key":"2026042618470701900_oyag129-B51","article-title":"Phase 1, firstin-human, open label, dose escalation ctudy of MGD009, a humanized B7-H3 x CD3 dual-affinity re-targeting (DART) protein in patients with B7-H3-expressing neoplasms or B7-H3 expressing tumor vasculature","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"2026042618470701900_oyag129-B52","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-17-1086","article-title":"Development of MGD007, a gpA33 x CD3-bispecific DART protein for T-cell immunotherapy of metastatic colorectal cancer","volume":"17","author":"Moore","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"2026042618470701900_oyag129-B53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"2026042618470701900_oyag129-B54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1093\/annonc\/mdy495","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","journal-title":"Ann Oncol"},{"key":"2026042618470701900_oyag129-B55","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"2026042618470701900_oyag129-B56","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"2026042618470701900_oyag129-B57","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/s41591-022-02015-7","article-title":"Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial","volume":"28","author":"Carvajal","year":"2022","journal-title":"Nat Med"},{"key":"2026042618470701900_oyag129-B58","doi-asserted-by":"publisher","first-page":"5869","DOI":"10.1158\/1078-0432.CCR-20-1247","article-title":"Tebentafusp, a tcr\/anti-CD3 bispecific fusion protein targeting gp100, potently activated antitumor immune responses in patients with metastatic melanoma","volume":"26","author":"Middleton","year":"2020","journal-title":"Clin Cancer Res"},{"key":"2026042618470701900_oyag129-B59","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"2026042618470701900_oyag129-B60","doi-asserted-by":"crossref","first-page":"e004225","DOI":"10.1136\/jitc-2021-004225","article-title":"Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology","volume":"10","author":"Zhou","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2026042618470701900_oyag129-B61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2026042618470701900_oyag129-B62","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2013assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2026042618470701900_oyag129-B63","doi-asserted-by":"crossref","first-page":"114075","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur J Cancer"},{"key":"2026042618470701900_oyag129-B64","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/s41408-023-00963-y","article-title":"Prophylactic tocilizumab to prevent cytokine release syndrome (CRS) with teclistamab: a single-center experience","volume":"13","author":"Scott","year":"2023","journal-title":"Blood Cancer J"},{"key":"2026042618470701900_oyag129-B65","doi-asserted-by":"crossref","first-page":"e000621","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026042618470701900_oyag129-B66","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"2026042618470701900_oyag129-B67","doi-asserted-by":"crossref","first-page":"e001014","DOI":"10.1136\/jitc-2020-001014","article-title":"LAG-3: from molecular functions to clinical applications","volume":"8","author":"Maruhashi","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026042618470701900_oyag129-B68","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"2026042618470701900_oyag129-B69","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc.2016.36","article-title":"Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy","volume":"16","author":"Topalian","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2026042618470701900_oyag129-B70","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/nri3862","article-title":"Molecular and cellular insights into T cell exhaustion","volume":"15","author":"Wherry","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2026042618470701900_oyag129-B71","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1158\/0008-5472.CAN-21-2483","article-title":"A probody T cell\u2013engaging bispecific antibody targeting EGFR and CD3 inhibits colon cancer growth with limited toxicity","volume":"82","author":"Boustany","year":"2022","journal-title":"Cancer Res"},{"key":"2026042618470701900_oyag129-B72","doi-asserted-by":"crossref","first-page":"207ra144","DOI":"10.1126\/scitranslmed.3006682","article-title":"Tumor-specific activation of an EGFR-targeting probody enhances therapeutic index","volume":"5","author":"Desnoyers","year":"2013","journal-title":"Sci Transl Med"},{"key":"2026042618470701900_oyag129-B73","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"2026042618470701900_oyag129-B74","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/14712598.2022.2098674","article-title":"Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development","volume":"22","author":"Chen","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2026042618470701900_oyag129-B75","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-018-0299-9","article-title":"Expanding the boundaries of biotherapeutics with bispecific antibodies","volume":"32","author":"Husain","year":"2018","journal-title":"BioDrugs"},{"key":"2026042618470701900_oyag129-B76","doi-asserted-by":"crossref","first-page":"108542","DOI":"10.1016\/j.celrep.2020.108542","article-title":"Exploitation of elevated extracellular ATP to specifically direct antibody to tumor microenvironment","volume":"33","author":"Mimoto","year":"2020","journal-title":"Cell Rep"},{"key":"2026042618470701900_oyag129-B77","doi-asserted-by":"crossref","first-page":"2395499","DOI":"10.1080\/19420862.2024.2395499","article-title":"IL-2-armored peptide-major histocompatibility class I bispecific antibodies redirect antiviral effector memory CD8+ T cells to induce potent anti-cancer cytotoxic activity with limited cytokine release","volume":"16","author":"Schardt","year":"2024","journal-title":"MAbs"},{"key":"2026042618470701900_oyag129-B78","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"key":"2026042618470701900_oyag129-B79","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1182\/blood-2018-02-830364","article-title":"Blinatumomab for MRD+ B-ALL: the evidence strengthens","volume":"131","author":"Brown","year":"2018","journal-title":"Blood"},{"key":"2026042618470701900_oyag129-B80","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.3390\/cancers15153955","article-title":"Early increase in circulating PD-1+CD8+ T cells predicts favorable survival in patients with advanced gastric cancer receiving chemotherapy","volume":"15","author":"Shin","year":"2023","journal-title":"Cancers (Basel)"},{"key":"2026042618470701900_oyag129-B81","first-page":"5619","article-title":"Oncolytic virus\u2013based bispecific T-cell engager therapy enhances antitumor immunity and reduces systemic toxicity","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag129\/67992731\/oyag129.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag129\/67992731\/oyag129.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/5\/oyag129\/67992731\/oyag129.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,26]],"date-time":"2026-04-26T22:47:21Z","timestamp":1777243641000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag129\/8644272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":81,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,4,10]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag129","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,4,8]]},"article-number":"oyag129"}}